UK MHRA: Drug Safety Update (November 2015)
There have been reports of severe, sometimes fatal, cases of cardiac failure in patients treated with crizotinib.
Prescribers should be aware of the risk of potentiation of radiation toxicity with vemurafenib when given before, during, or after radiotherapy.
In October 2015, letters were sent to healthcare professionals to provide safety information for the anticancer medicines crizotinib and vemurafenib.
Posted on the UK MHRA website on 12 November 2015